Catalytic antibodies in patients with systemic lupus erythematosus

- Dimethylarginines in vasculitis
- Muscle loss following IM steroid injection for RA flare
- Hidradenitis suppurativa and inflammatory eye disease
- Comorbidities in Argentine patients with axial spondyloarthritis
- Catalytic antibodies in Indian patients with SLE
- Fertility in women with rheumatoid arthritis
- Risk factor assessment of rheumatoid arthritis in North Kerala
Editor in Chief
George C. Tsokos
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Associate Editors
Hèctor Corominas
Servei de Reumatologia, Hospital Moisés Broggi, Barcelona, Catalonia, Spain; Division of Rheumatology and Lupus Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Bünyamin Kısacık
Department of Rheumatology, Gaziantep Medical Park Hospital, Gaziantep, Turkey

Seung-Ki Kwok
Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea

Roger A. Levy
Department of Rheumatology, The State University of Rio de Janeiro, Rio De Janeiro, Brazil

Stmatis-Nick Liossis
Division of Rheumatology, University of Patras School of Medicine, Patras University Hospital, Patras, Greece

Ahmet Mesut Onat
Professor in Rheumatology, Gaziantep, Turkey

Amr H. Sawalha
Division of Rheumatology, Department of Internal Medicine; Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA

Amir Sharabi
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Clinical Immunology, Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel

Yusuf Yazıcı
NYU Hospital for Joint Diseases, New York, NY USA

Statistical Editor
İsmail Sarı
Department of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey

Owner and Responsible Manager
Ahmet Mesut Onat
Professor in Rheumatology

Editorial Board

Julian Ambrus
Division of Allergy, Immunology and Rheumatology, Buffalo School of Medicine, Buffalo, NY, USA

Iannis Adamopoulos
Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis School of Medicine, California, USA

Nurullah Akkoç
Division of Rheumatology and Immunology, Department of Internal Medicine, Dokuz Eylül University School of Medicine, Izmir, Turkey

Sibel Zehra Aydın
Division of Rheumatology, Ottawa University School of Medicine, Ottawa, Canada

Ernest Brahn
Department of Rheumatology, UCLA School of Medicine, CA, USA

Dimitrios Boumpas
Department of Internal Medicine and Rheumatology, Clinical Immunology and Allergy, University of CretE, CretE, Greece

Juan Jesus Gomez Reino Carnata
Division of Rheumatology, Department of Medicine, Hospital Clínico Universitario, Choupana, Santiago de Compostela, Spain

David D Cruz
Louise Coote Lupus Unit, St Thomas’ Hospital, London, UK

Haner Direskeneli
Department of Rheumatology, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey

Paul Emery
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Doruk Erkan
Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA

Eugen Feist
Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany

Cem Gabay
Division of Rheumatology, Geneva University Hospitals, Geneva, Italy

Francesco Del Galdo
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Leeds, UK

Conchi Castillo Gallego
Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain

Tamer A. Gheita
Department of Rheumatology, Cairo University School of Medicine, Giza, Egypt

Allan Gibofsky
Clinic of Rheumatology, Hospital for Special Surgery, New York, NY, USA

Dennis Mc Gonagle
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Leeds, UK

Vedat Hamuryudan
Division of Rheumatology, Department of Internal Medicine, Istanbul University School of Medicine, Istanbul, Turkey

Christian Hedrich
Department of Pediatric Rheumatology & Immunology, Carl Gustav Carus University Medical Center, Dresden, Germany

Vasilieos C. Kytarris
Division of Rheumatology, Harvard Medical School Beth Israel Deaconess Medical Center, Boston, MA, USA

Nicholas Manolios
Department of Rheumatology, Westmead Hospital, Sydney, Australia

Hilal Maradit Kremers
Department of Health Sciences Research, Collage of Medicine, Mayo Clinic, Minnesota, USA

Marco Mattucci-Cerinic
Department of Experimental and Clinical Medicine, Division of Rheumatology, AOUC, University of Florence, Florence, Italy

Pier Luigi Meroni
Department of Rheumatology, University of Milan Clinical Sciences and Community Health, Milan, Italy

Pierre Miossec
Clinical Immunology and Rheumatology Unit, University of Lyon, Lyon, France

Peter Nash
Physician And Rheumatologist, University Of Queensland School of Medicine, Brisbane, QL, Australia

Seza Özen
Division of Pediatric Rheumatology, Department of Child Health and Diseases, Hacettepe University School of Medicine, Ankara, Turkey

Antonio Gonzales Martinez Pedroya
Division of Rheumatology, Department of Medicine, Hospital Clínico Universitario, Choupana, Santiago de Compostela, Spain

Carlo Perricone
Department of Rheumatology, Sapienza University of Rome, Rome, Italy

Claus Rasmussen
Department of Biocience, Aarhus University, Aarhus, Denmark

Carlo Salvarani
Servizio di Reumatologia, Azienda Ospedaliera Arcispedale S. Maria Nuova, Emilia, Italy

Nancy Ann Shadick
Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Yehuda Shoenfeld
Zabulovics Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Sekib Sokolovic
Clinic for Heart Diseases and Rheumatism, Clinical Center of University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Isaac Ely Stillman
Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

John H. Stone
Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Elias Toubi
Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel

Konstantinos Tselios
Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

Panayiotis Vlachoyiannopoulos
National and Kapodistrian University of Athens, Athens, Greece

Alvin Wells
Board-certified Rheumatologist Director, Rheumatology and Immunotherapy Center, Franklin, WI, USA

Hasan Yazıcı
Department of Rheumatology, Istanbul University School of Medicine, Istanbul, Turkey

Hilal Maradit Kremers
Department of Health Sciences Research, Collage of Medicine, Mayo Clinic, Minnesota, USA
AIMS AND SCOPE

European Journal of Rheumatology (Eur J Rheumatol) is an international, open access peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on March, June, September and December.

The aim of the European Journal of Rheumatology is to cover various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoinflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case reports, letters to the editor and images in rheumatology. The publication language of the journal is English.

The journal’s target audience includes academicians, practitioners, specialists and students from all disciplines of rheumatology.

European Journal of Rheumatology adheres to the principles outlined by the guidelines of ICMJE, WAME, EASE and COPE.

European Journal of Rheumatology is currently indexed in PubMed Central, Web of Science-Emerging Sources Citation Index, EBSCO and CINAHL.

All published content of the European Journal of Rheumatology is available online at eurjrheumatol.org, free of charge.

Statements or opinions expressed in the manuscripts published in the European Journal of Rheumatology reflect the views of the author(s) and not the opinions of the editors, the editorial board and the publisher; the editors, the editorial board and the publisher disclaim any responsibility or liability for such materials.

The journal is printed on an acid-free paper.

Permission requests for reproduction of materials published, reprint requests and requests concerning advertising should be addressed to the publisher;

Address: Büyükdere Cad. 105/9 34394 Mecidiyeköy, Şişli, İstanbul, Turkey
Phone: +90 212 217 17 00
Fax: +90 212 217 22 92
e-mail: info@avesyayincilik.com
avesyayincilik.com
European Journal of Rheumatology (Eur J Rheumatol) is an international, open access, peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on March, June, September and December. The journal covers various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoinflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case reports, letters to the editor and images in rheumatology. The publication language of the journal is English.

The members of reviewer board of the journal are selected from independent international authorities and experts. The editorial board requests the assistance of the reviewer board while selecting manuscripts for publication.

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their coauthors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged in the title page of the manuscript.

European Journal of Rheumatology requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through www.eurjrheumatol.org) during the initial submission process in order to act appropriately to authorship rights and prevent ghost or honorary authorship.

Any financial grants or other support received for the study should be disclosed to the Editorial Board and to disclose potential conflicts of interest ICMJE Potential Conflict of Interest Disclosure Form (available at www.icmje.org) should be filled in and submitted during the initial submission process. Cases of potential conflicts of interest of editors, authors and reviewers are resolved by the Journal's Editorial Board within the scope of COPE and ICMJE guidelines.

An*Author Contribution Form* is required with all submissions. A statement on absence of conflict of interests are required. (ICMJE Form for Disclosure of Potential Conflicts of Interest and Authorship Contributions forms are available at www.eurjrheumatol.org).

The journal's editorial and publication processes are adherent to the guidelines of the international organizations such as ICMJE, WAME, COPE and EASE. European Journal of Rheumatology requires authors to acknowledge and provide information on grants, contracts or other financial support of the study provided by any foundations and institutions or firms.

Manuscripts that have been published previously elsewhere or are currently under consideration in other journals will not be evaluated and these type of submissions will be returned to the submitting author. All manuscripts are checked for plagiarism, replication, and duplicate publication. The retraction requests of manuscripts without reasonable explanation will result in "reject" decision if the manuscript is under consideration for publication and close to the final decision.

By submitting a manuscript to European Journal of Rheumatology author acknowledge that the editors could make corrections without changing the basic meaning of the text of the manuscript.

To be accepted for publication, it is required that manuscripts should be original and of high scientific and academic quality, with probability of being cited.

**Manuscript Submission**

European Journal of Rheumatology only evaluates manuscripts submitted via the journal's self-explanatory submission system available through www.eurjrheumatol.org. Manuscripts submitted via any other medium will not be evaluated.

If a manuscript was previously submitted to another publication for evaluation, it is advised that the authors provide the previous evaluation reports during submission to facilitate the evaluation process.

Prior to the evaluation process, each submission goes through a technical review process where the manuscript's general format is checked against the journal's general guidelines. Manuscripts that do not comply with the journal's guidelines will be returned to the submitting author with correction requests and will not undergo peer-review before the requested corrections are implemented.

Following the peer-review process, if a revision is requested, authors are required to return the revised manuscript within 21 days for minor revision decisions and 45 days for major revision decisions. If the authors think that the allocated time is not sufficient to implement the corrections, a deadline extension should be requested from the editorial office before the due date.

Manuscript format should be in accordance with Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (updated in December 2017 - http://www.icmje.org/icmje-recommendations.pdf).

The filled authorship contributions form must be submitted along with the manuscript. The journal's rules on authorship contributions are in compliance with CSE (http://www.councilscienceditors.org/4a/pages/index.cfm?pageid=3376) and ICMJE (http://www.icmje.org/ethical_1author.html) recommendations.

Original Investigations and Reviews should be presented according to the following guidelines: randomized study - CONSORT; observational study - STROBE, study on diagnostic accuracy - STARD, systematic reviews and meta-analysis PRISMA, animal experimental studies - ARRIVE, non-randomized behavioural and public health intervention studies - TREND.

**Manuscript Preparation**

**Title Page**

Each submission should be accompanied by a title page. The document should be submitted separately through the submission system and should include the title of the manuscript, running head, a full list of all contributing authors, full institution information of all contributing authors, an address for correspondence, contact information of the corresponding author (including the contact phone number, mobile phone number and the e-mail address), if the content of the manuscript has been presented before the time and place of the presentation and the acknowledgements if there are any. Acknowledgement to persons who significantly contributed to the study or assisted in preparing article should be done appropriately.

**Abstract**

The abstract should be limited to 400 words for original articles and review articles and should be limited under 250 words for case reports. Abstracts of original articles should be structured with the following subheadings: Objective, Material and Methods, Results and Conclusion.
Keywords
All submissions should be accompanied by 3 to 6 keywords concordant with NLM MeSH vocabulary terms (available at http://www.nlm.nih.gov/mesh/MBrowser.html)

Main Document
Main document should include the main text, reference list and the tables. It should be prepared using Microsoft Word software. Times New Roman font (size 12) should be used throughout the main document with 1.5 line spacing. The side margins of the main document should be set at 25 mm from all sides.

Main text
The main text should be structured depending on the type of the manuscript. The main text of original articles should be structured with Introduction, Methods, Results and Discussion subheadings while the main text of case reports should be structured with Introduction, Case Presentation and Discussion subheadings. These sections can be divided into subsections and subtitles where appropriate. With original articles, the limitations of the study should be provided under the Discussion section, before the conclusion paragraph.

The main text of original articles should not exceed 3000 words and should be accompanied by necessary number of tables and figures. The number of references cited in an original article should be limited to 35.

With review articles, the main text should not exceed 5000 words and should be accompanied by necessary number of tables and figures. The number of references cited in an original article should be limited to 50.

Case reports should not be longer than 1200 words, and the number of references should be limited to 10.

Letters to the Editor and Images in Rheumatology should not be longer than 500 words. The number of references should be limited to 5 with these kinds of manuscripts.

The main text of all manuscripts should be blind. Any information that may indicate an individual or institution should be excluded.

Information on informed consent of the patients and ethics committee approval should be provided under the Material and Methods section of the main text.

Statistical analysis should be performed in accordance with guidelines on reporting statistics in medical journals (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J 1983; 7: 1489-93). Software used for analysis should be described. For parametric tests represent continuous variables as Means±Standard Deviation, while for non-parametric tests represent data as Median and range (Minimum-Maximum) or Median and interquartile range (25th and 75th percentiles). Whenever complex analyses are used support the relative risk, odds or hazard ratios values by providing confidence intervals and p values.

When a drug, product, hardware, or software mentioned within the main text product information, including the name of the product, producer of the product, city of the company and the country of the company should be provided in parenthesis in the following format: “Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)”

All references, tables and figures should be referred to within the main text. All acronyms and abbreviations should be defined at first use within the main text followed by the acronym or abbreviation in parenthesis.

References
References should be numbered in the order they are referred to within the main text. Authors are responsible for accuracy of references.

Reference Formatting
Standard journal article: Abbreviations of journal titles should be done in accordance with journal abbreviations used in Index Medicus for (journal abbreviations consult List of Journals indexed for MEDLINE published annually by NLM at http://www.nlm.nih.gov/mesh/serials/f.html). In case of six or less authors numbers list of all authors is required. If number of authors exceeds six, list first 6 authors followed by et al. A list of authors should be followed by the full title of the article, journal title, year, volume and page numbers.


Editor (s), compiler(s) as author: Norman IJ, Redfern SJ, editors. Mental Health Care for Elderly People. New York: Churchill Livingstone; 1996.


Tables
Tables should be included at the end of the main document and should not be submitted separately. Each table should be accompanied by a descriptive title. Abbreviations used in tables should be defined below the tables by footnotes. All tables should be referred to within the main text and they should be numbered consecutively in the order they are referred to.

Figures
Figures should be submitted as separate files through the submission system and they should not be embedded in the main document. Each figure should be accompanied by a descriptive legend. When there are subunits, the subunits should not be merged to form a single image but should be submitted through the submissions system. Submitted images should be clear and large in size with a minimum width of 15 cm. The minimum resolution of each submitted image should be 300DPI. Like the rest of the manuscript, the figures too should be blind. All information that may indicate individual or institution should be excluded.

The originality of tables and figures should be confirmed in the accompanying letter. In case of reproduction of tables and figures from other published sources, the appropriate citation should be done and the original source either in hardcopy or electronic (“.pdf” format along with the obtained permission for publication from Copyright owner (publisher, journal or author(s) should be submitted to the Editor-in-Chief office.

The rules for title page, references, figures and tables are applicable for all types of manuscripts.
CONTENTS

**Original Articles**

153 Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis
Uta Erdbrügger, Jan T. Kielstein, Kerstin Westman, Jennie Z. Ma, Wenjun Xin, Stephanie M. Bode-Böger, Mårten Segelmark, Niels Rasmussen, Kirsten de Groot

160 Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis

165 Characteristics of inflammatory eye disease associated with hidradenitis suppurativa

169 Comorbidities in Argentine patients with axial spondyloarthritis: Is nephrolithiasis associated with this disease?
Fernando Sommerfleck, Emike Schneeberger, Gustavo Citera

173 Catalytic antibodies in patients with systemic lupus erythematosus
Vandana Pradhan, Pallavi Pandit, Prathamesh Surve, Maxime Lecerf, Anjali Rajadhyaksha, Milind Nadkar, Prasad V. Khadilkar, Durga A. Chougule, Aalaap A. Naigaonkar, Sébastien Lacroix-Desmazes, Jagadeesh Bayry, Kanjaksha Ghosh, Srini V. Kaveri

179 Is rheumatoid arthritis an innocent bystander in female reproductive problems? A comparative study of fertility in Nigerian women with and without rheumatoid arthritis
Richard Oloyinka Akintayo, Olufemi Opeyemi Aworinde, Osaze Ojo, Foluke Comfort Akintayo, Olavale Matthias Akinlade, Rasheed Olaide Awodun, Sakiru Oyetunji Isi

184 Risk factor assessment of rheumatoid arthritis in North Kerala
Binoy Paul, Rosh Pariyapurath

**Literature Review**

191 Symmetric polyarthritis as an initial symptom in granulomatosis with polyangiitis: A report of six cases and review of the literature
Bünyamin Kısacık, Mustafa Erkut Önder, Mehmet Sayarlioğlu, Ahmet Mesut Onat

**Case Reports**

194 Anti-Ro antibodies and complete heart block in adults with Sjögren’s syndrome
Kerry Jobling, Hanaa Rajabally, Wan-Fai Ng

197 Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association
Tarek Carlos Salman-Monte, Irene Carrión-Barberà, Carolina Pérez García, Javier Gimeno Beltrán, Jordi Monfort
CONTENTS

201 First case of demyelinating polyneuropathy probably related to treatment with golimumab
   Francisco Javier Domínguez Diez

203 Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with
   rheumatoid arthritis
   Göksel Güven, Aslıhan Guler, Nil Özyüncü, Leyla Talan, Aylin Heper, Tahsin Murat Turgay, Neriman Defne Altıntaş

206 A case of exogenous ochronosis associated with hydroxychloroquine
   Emre Tekgöz, Egemen Akıncıoğlu, Muhammet Çınar, Sedat Yılmaz

Letter to the Editor

209 Aortic aneurysm and dissection in systemic lupus erythematosus—pathophysiologic and
   therapeutic considerations
   Nicholas G. Kounis, Ioanna Koniari, Dimitrios Velissaris, George Soufras, George Hahalis

Images in Rheumatology

212 Acrometastasis as the first manifestation of lung carcinoma
   Mohammed El Idrissi, Nessrine Akasbi, Abdelhalim Elibrahimi, Abdelmajid Elmrini

214 Dacrocystitis and orbital pseudotumor in a patient with Granulomatosis with polyangiitis
   Sajal Ajmani, Abhishek Zanwar, Pradeepa Patro, Able Lawrence